SEC Form 4 · accession 0000899243-18-027919
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Glenn Goddard
Officer — SEE REMARKS
Period of report
Nov 1, 2018
Accepted (ET)
Nov 1, 2018 · 6:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $19.27 | Nov 1, 2018 | A | 90,000 | A | — | Oct 31, 2018 | Common Stock | 90,000 | 90,000 | D |
Explanation of responses
- F1This option was granted on November 1, 2018 with respect to 90,000 shares of Common Stock, with 25% vesting on November 1, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
Remarks
Executive Vice President, Chief Financial Officer